



Cuvposa® (glycopyrrolate) – First-time generic

- On January 4, 2022, [Par Pharmaceutical](#) launched an [AA-rated](#) generic version of Merz Pharmaceuticals' [Cuvposa \(glycopyrrolate\)](#) oral solution.
- Cuvposa is approved to reduce chronic severe drooling in patients aged 3 to 16 years with neurologic conditions associated with problem drooling (eg, cerebral palsy).
- Oral glycopyrrolate is also available generically as a [tablet](#).
- The oral tablet is approved as adjunctive therapy in the treatment of peptic ulcer.
- According to IQVIA™, Cuvposa sales were approximately \$27 million for the 12 months ended October 31, 2021.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2022 Optum, Inc. All rights reserved.